NAD+ and Glutathione are having a moment in wellnessand for good reason
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS
Don't limit your progress, make an appointment with Dr Anderson today to get started
As research progresses, Dihexas role in enhancing cognitive function and supporting brain health may soon redefine treatment strategies across the globe
The practical implication: Published pharmacokinetic comparisons show that IV glutathione produces a ~47-fold plasma elevation within minutes, while standard oral capsules produce minimal measurable change
Theoretical concerns based on pharmacology include: Somatostatin-like effects -- binding sst1-5 could theoretically suppress GH release, insulin secretion, and glucagon release, though cortistatin's short half-life may limit systemic exposure Ghrelin receptor activation -- GHSR-1a activation could theoretically influence appetite and metabolism Unknown systemic effects -- the absence of any human administration data means that unexpected adverse effects cannot be excluded DSIP Side Effects# Limited human safety data from small studies: Headache -- occasionally reported Morning grogginess -- reported at higher doses, consistent with a sleep-promoting effect persisting beyond the intended sleep period Generally well-tolerated -- across the limited studies conducted, no serious adverse events have been attributed to DSIP No systematic safety characterization -- the absence of formal adverse event reporting, long-term follow-up, and immunogenicity testing means the safety profile is incompletely characterized Practical Applicability Comparison# Cortistatin# Cortistatin faces substantial practical barriers to sleep application: Route of administration -- all sleep studies used intracerebroventricular injection, which is only feasible in controlled research settings Short half-life -- rapid degradation in vivo limits duration of effect Somatostatin receptor cross-reactivity -- binding sst1-5 introduces potential metabolic and endocrine effects that complicate clinical development Research-grade only -- available only as a research peptide, not manufactured for clinical use Analog development -- structure-based analogs with improved selectivity and pharmacokinetics are being investigated but remain preclinical DSIP# DSIP is more practically accessible but still limited: Subcutaneous administration -- a clinically feasible route, unlike cortistatin's ICV requirement Available from research suppliers -- can be obtained, though quality varies between sources Very short half-life -- approximately 7-8 minutes, raising questions about whether meaningful sleep effects can be achieved given the rapid degradation No standardized protocol -- typical doses of 100-500 mcg pre-sleep are empirically derived, not established through dose-finding studies Stability concerns -- DSIP degrades in solution, adding practical challenges to preparation and storage Mechanism Specificity Comparison# This category highlights a fundamental scientific difference between the two peptides
